WSE:DRF

Stock Analysis Report

Executive Summary

Dr.Finance S.A. provides financial products and services for individuals and businesses in Poland.

Snowflake

Fundamentals

Good value with proven track record.

Share Price & News

How has Dr.Finance's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

20.0%

DRF

1.4%

PL Capital Markets

2.1%

PL Market


1 Year Return

-23.4%

DRF

-16.3%

PL Capital Markets

-2.7%

PL Market

Return vs Industry: DRF underperformed the Polish Capital Markets industry which returned -16.3% over the past year.

Return vs Market: DRF underperformed the Polish Market which returned -2.7% over the past year.


Shareholder returns

DRFIndustryMarket
7 Day20.0%1.4%2.1%
30 Day9.1%-5.8%-1.6%
90 Dayn/a-7.6%-6.9%
1 Year-23.4%-23.4%-10.1%-16.3%0.2%-2.7%
3 Year-12.2%-12.2%-16.5%-29.0%12.1%4.1%
5 Year-60.7%-64.0%-30.5%-41.4%-0.5%-12.5%

Price Volatility Vs. Market

How volatile is Dr.Finance's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dr.Finance undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: DRF (PLN0.36) is trading below our estimate of fair value (PLN1.88)

Significantly Undervalued: DRF is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DRF is good value based on its PE Ratio (8.7x) compared to the Capital Markets industry average (23.3x).

PE vs Market: DRF is good value based on its PE Ratio (8.7x) compared to the Polish market (10.1x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate DRF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DRF is overvalued based on its PB Ratio (2.4x) compared to the PL Capital Markets industry average (1.1x).


Next Steps

Future Growth

How is Dr.Finance forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

1.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRF's forecast earnings growth (1.5% per year) is below the savings rate (2.9%).

Earnings vs Market: DRF's earnings (1.5% per year) are forecast to grow slower than the Polish market (10.6% per year).

High Growth Earnings: DRF's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if DRF's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if DRF's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if DRF's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dr.Finance performed over the past 5 years?

64.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DRF has become profitable over the past 5 years, growing earnings by 64.5% per year.

Accelerating Growth: DRF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DRF had negative earnings growth (-79.2%) over the past year, making it difficult to compare to the Capital Markets industry average (-61.7%).


Return on Equity

High ROE: DRF's Return on Equity (27.5%) is considered high.


Return on Assets

ROA vs Industry: DRF has a higher Return on Assets than the Capital Markets industry average last year.


Return on Capital Employed

ROCE Improving: DRF has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Dr.Finance's financial position? (This company is analysed differently as a bank or financial institution)


Financial Position Analysis


Debt to Equity History and Analysis


Balance Sheet

Inventory Level: DRF has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DRF's debt is covered by short term assets.


Financial Institutions Analysis

Asset Level: DRF's level of assets compared to its equity is low.

Allowance for Bad Loans: Insufficient data to determine if DRF has a sufficient allowance for bad loans.

Low Risk Liabilities: DRF reports no customer deposits, loans are made up entirely of externally borrowed funds.

Loan Level: Insufficient data to determine if DRF has an acceptable proportion of non-loan assets held.

Low Risk Deposits: DRF has advanced significantly more loans than the customer deposits it holds.

Level of Bad Loans: Insufficient data to determine if DRF has an appropriate level of bad loans.


Next Steps

  • Explore more healthy companies in the Diversified Financials industry.

Dividend

What is Dr.Finance's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.6%markettop25%7.2%industryaverage3.5%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DRF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DRF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DRF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRF's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

What is the CEO of Dr.Finance's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average board tenure


CEO

Pawel Wozniak 0

0yrs

Tenure

0

Mr. Pawel Wozniak serves as President of Management Board of Doradcy24 S.A. Mr. Wozniak has been President of the Management Board at Polcredito Sp. z o.o. since 2010. He has been Vice-President of the Man ...


Board Age and Tenure

0.8yrs

Average Tenure

Experienced Board: DRF's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Pawel Wozniak

    President of Management Board

    • Tenure: 0yrs
  • Pawel Szponik

    Secretary of the Supervisory Board & Member of the Supervisory Board

    • Tenure: 0.8yrs

Board Members

  • Jerzy Dera

    Chairman of Supervisory Board

    • Tenure: 0yrs
  • Lukasz Jagiello

    Vice Chairman of Supervisory Board

    • Tenure: 0.8yrs
  • Michal Swiatek

    Member of the Supervisory Board

    • Tenure: 3.5yrs
  • Pawel Szponik

    Secretary of the Supervisory Board & Member of the Supervisory Board

    • Tenure: 0.8yrs

Company Information

Dr.Finance S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dr.Finance S.A.
  • Ticker: DRF
  • Exchange: WSE
  • Founded:
  • Industry: Asset Management and Custody Banks
  • Sector: Diversified Financials
  • Market Cap: zł1.346m
  • Shares outstanding: 3.74m
  • Website: https://drfinance.pl

Location

  • Dr.Finance S.A.
  • ul. Legnicka 17/27
  • Wroclaw
  • 53-671
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DRFWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNJul 2008

Biography

Dr.Finance S.A. provides financial products and services for individuals and businesses in Poland. It offers mortgages, cash and car loans, investment and insurance products, revolving credit, credit for d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 21:05
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.